ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 151

Severe Phenotype of Mevalonate-kinase Deficiency in the Czech Republic

Sarka Fingerhutova1, Lenka Dvorakova2, Petr Chrastina2, Eva Jancova3, Petra Keslova4, Adam Klocperk5, Marcel Schuller6, Alexander Kolsky7 and Pavla Dolezalova1, 1Paediatric Rheumatology Unit, General University Hospital in Prague and 1st Faculty of Medicine, Charles University, General University Hospital in Prague and 1st Faculty of Medicine, Prague, Czech Republic, 2Institute of Inherited Metabolic Disorders, Institute of Inherited Metabolic Disorders, 1 st Faculty of Medicine Charles University and General University Hospital in Prague, Prague, Czech Republic, 3Department of Nephrology, General University Hospital in Prague and 1st Faculty of Medicine, Prague, Czech Republic, 4Department of Paediatric Haematology and Oncology, 2 nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, 2 nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic, 5Department of Immunology, 2 nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, 2 nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic, 6Paediatric Rheumatology Unit, University Hospital Brno, Brno, Czech Republic, 7Department of Children and Adolescents, 3 rd Faculty od Medicine, Charles University in Prague, Prague, Czech Republic

Meeting: 2017 Pediatric Rheumatology Symposium

Keywords: AA-amyloidosis, biologic drugs and fever

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Thursday, May 18, 2017

Title: Genetics and Pathogenesis Poster Session

Session Type: Abstract Submissions

Session Time: 5:30PM-7:00PM

Background/Purpose:  Disease phenotype of mevalonate-kinase (MVK) deficiency (MKD) varies in relation to the extent of enzymatic activity reduction. It ranges from multi-organ involvement with fatal outcome in mevalonic aciduria to variably severe periodic fever of hyper-IgD syndrome (HIDS). Since the establishment of our fever clinic in 2004 eight patients were diagnosed with HIDS. In 5 out of them clinical course was severe enough to require biologic therapy. Such a disease severity in our cohort lead us to search for additional patients followed at other institutions in order to learn about potential specific disease features in the Czech population.

Methods: Only one specialized laboratory in the country provides urine MVA measurement and since 2012 also MVK gene analysis. All patients with positive MVA detected between Jan 2004 and Dec 2016 and/or those with 2 MVK gene mutations were retrieved and their electronic records reviewed by treating physicians.

Results: : Five patients from 2 other institutions were identified on top of the original 8 cases (11 females), all Caucasians. Only patients with MKD phenotype and/or confirmed MVK mutations had positive urine MVA. Median age at onset was 15 (1-36) months, diagnostic delay was 8.2 (1-25.5) years. (Table) Gastrointestinal and joint symptoms were present in 54 and 62% of cases, respectively, 7 patients (54%) had cervical lymphadenopathy and 5 (38%) splenomegaly. “Severe” symptoms that lead to the introduction of biologics in 7 patients included high episode frequency interfering with daily activities (n=6), splenomegaly (n=3) and renal amyloidosis with onset at 5 years of age (n=1, patient 6). Patient 12 died in early infancy with the picture of fulminant HLH. When her younger sister presented with similar symptoms at 3 weeks of age she rapidly received HSCT for suspected unknown primary HLH. Only after her recovery results of the WES became available and confirmed MKD, which was then found also in her sister’s stored DNA. Patient 5 had nearly complete resolution of symptoms without therapy during her uneventful pregnancy and gave birth to healthy twins. Her disease returned post-delivery in full severity and her treatment response remains unsatisfactory.

Conclusion:  : Over the past 12 years 13 Czech patients were diagnosed with MKD. The genotype spectrum was similar to that reported with the p.V377I mutation being the most prevalent. Unlike other series, high proportion of patients (n=9, 69%) had severe or life-threatening phenotype requiring biologic therapy or HSCT. We learned that macrophage activation triggered by MKD may mimic primary HLH in neonatal period and that amyloidosis may complicate untreated MKD very early. Similarities with the more common and benign PFAPA syndrome have lead us to screen all suspected PFAPA patients for urine MVA.


Disclosure: S. Fingerhutova, None; L. Dvorakova, None; P. Chrastina, None; E. Jancova, None; P. Keslova, None; A. Klocperk, None; M. Schuller, None; A. Kolsky, None; P. Dolezalova, None.

To cite this abstract in AMA style:

Fingerhutova S, Dvorakova L, Chrastina P, Jancova E, Keslova P, Klocperk A, Schuller M, Kolsky A, Dolezalova P. Severe Phenotype of Mevalonate-kinase Deficiency in the Czech Republic [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 4). https://acrabstracts.org/abstract/severe-phenotype-of-mevalonate-kinase-deficiency-in-the-czech-republic/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/severe-phenotype-of-mevalonate-kinase-deficiency-in-the-czech-republic/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology